Friday, 22 October 2021 11:55

Drench company to cease NZ production in 2022

Written by  Staff Reporters
Boehringer Ingelheim Animal Health will cease production from its Auckland site from December 2022. Boehringer Ingelheim Animal Health will cease production from its Auckland site from December 2022.

Boehringer Ingelheim says it will stop manufacturing locally-produced livestock ruminant products in New Zealand by late 2022 - ending more than 50 years of local production.

The animal health company says it will cease production from its Auckland site from December 2022. It says it will deliver a more 'targeted' range of cattle and sheep products, including brands such as Eprinex, Eclipse and Bionic Plus. However, the company adds that some of these products will be produced locally by contract manufacturing partners in New Zealand.

Meanwhile, the company says it will continue to distribute therapeutic medicines such as Metacam, Bivatop and Mamyzin - along with its range of swine vaccines and companion animal products, such as NexGard and Broadline.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with a presence in more than 150 countries.

NZ country manager Steve Rochester says the company will work with veterinarians, farmers and stakeholders across New Zealand through to December 2022. He is promising to deliver a comprehensive business support plan to help with the transition.

"Boehringer Ingelheim, and before that Merial Ancare, has been an integral member of the New Zealand animal health industry for over 50 years," Rochester says.

"We recognise this announcement is a significant change for members of the Boehringer Ingelheim team, farmers, veterinarians and the wider agricultural industry."

He says the company wanted to communicate the decision as early as possible to ensure those affected have the time to consider what this change means for them.

"Our team will be partnering closely with our customers and industry stakeholders over the coming months and will continue to share information as decisions are made," Rochester adds.

"We want to reassure our customers that we will work closely with them to provide ongoing business support and meet their product requirements during this transition period."

He adds that the company will continue to produce and supply its full range of livestock products and deliver on commercial agreements over the coming year.

He adds that Boehringer Ingelheim will continue to invest in the research and development of new breakthrough therapies for the health and wellbeing of animals.

"For many decades, Boehringer Ingelheim has provided New Zealand farmers and pet owners innovative medicines, products and services to support the health and wellbeing of their animals," says Rochester.

"We are committed to building on those strong partnerships and provide innovative animal health solutions into the future."

More like this

Calls for more support for vets, nurses

The animal health sector needs to change to keep up with the times, according to the discussion at a breakfast event hosted by Boehringer Ingelheim at the NZ Vet Association and NZ Veterinary Nursing Association conference in Christchurch recently.

Featured

Farmers urged not to be complacent about TB

New Zealand's TBfree programme has made great progress in reducing the impact of the disease on livestock herds, but there’s still a long way to go, according to Beef+Lamb NZ.

Editorial: Making wool great again

OPINION: Otago farmer and NZ First MP Mark Patterson is humble about the role that he’s played in mandating government agencies to use wool wherever possible in new and refurbished buildings.

National

Machinery & Products

Farmer-led group buys Novag

While the name and technology remain unchanged and new machines will continue to carry the Novag name, all the assets,…

Buhler name to go

Shareholders at a special meeting have approved a proposed deal that will see Buhler Industries, the publicly traded Versatile and…

» Latest Print Issues Online

The Hound

Make it 1000%!

OPINION: The appendage swinging contest between the US and China continues, with China hitting back with a new rate of…

Own goal

OPINION: The irony of President Trump’s tariff obsession is that the worst damage may be done to his own people.

» Connect with Rural News

» eNewsletter

Subscribe to our weekly newsletter